Comparison of Early Morbidity and Mortality Between Sleeve Gastrectomy and Gastric Bypass in High-Risk Patients for Liver Disease: Analysis of American College of Surgeons National Surgical Quality Improvement Program
Chronic liver disease is prevalent in obese patients presenting for bariatric surgery and is associated with increased postoperative morbidity and mortality (M&M). There are no comparative studies on the safety of different types of bariatric operations in this subset of patients.
The aim of this study is to compare the 30-day postoperative M&M between laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-Y-gastric bypass (LRYGB) in the subset of patients with a model of end-stage liver disease (MELD) score ≥ 8.
Data for LSG and LRYGB were extracted from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database from years 2012 and 2013. MELD score was calculated using serum creatinine, bilirubin, INR, and sodium. Postoperative M&M were assessed in patients with a score ≥ 8 and compared for the type of operation. This was followed by analysis for MELD subcategories. Multiple logistic regression was performed to adjust for confounders.
Out of 34,169, 9.8% of cases had MELD ≥ 8 and were included. Primary endpoint, 30-day M&M, was significantly lower post-LSG (9.5%) compared to LRYGB (14.7%); [AOR = 0.66(0.53, 0.83)]. Superficial wound infection, prolonged hospital stay, and unplanned readmission were more common in LRYGB. M&M post-LRYGB (30.6%) was significantly higher than LSG (15.7%) among MELD15-19 subgroup analysis.
LRYGB is associated with a higher postoperative risk than LSG in patients with MELD ≥ 8. The difference in postoperative complications between procedures was magnified with higher MELD. This suggests that LSG might be a safer option in morbidly obese patients with higher MELD scores, especially above 15.
KeywordsLiver disease MELD score Sleeve gastrectomy Gastric bypass Bariatric surgery
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
De-identified patient information is freely available to all institutional members who comply with the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) Data Use Agreement. The Data Use Agreement implements the protections afforded by the Health Insurance Portability and Accountability Act of 1996 and the ACS NSQIP Hospital Participation Agreement, and conforms to the Declaration of Helsinki.
For this type of study on de-identified datasets, formal consent is not required.
ACS NSQIP Disclaimer
The American College of Surgeons National Surgical Quality Improvement Program and the hospitals participating in the ACS NSQIP are the source of the data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.
- 1.World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: WHO; 2014.Google Scholar
- 3.Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. Journal of clinical gastroenterology. 2006;40:S5–S10.Google Scholar
- 7.Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Surg Obes Relat Dis. 2013;9(2):159–91.CrossRefGoogle Scholar
- 10.Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005;242(4):610.Google Scholar
- 18.Zielsdorf SMMD, Kubasiak JCMD, Janssen IP, et al. A NSQIP Analysis of MELD and Perioperative Outcomes in General Surgery. Am Surg. 2015;81(8):755–9.Google Scholar
- 24.Clerical Changes for Implementation of Adding Serum Sodium to the MELD Score, Policy 9.1.D, (2016).Google Scholar
- 42.Tarantino I, Barresi L, Petridis I, Volpes R, Traina M, Gridelli B. Endoscopic treatment of biliary complications after liver transplantation. World J Gastroenterol. 2008;14(26).Google Scholar